NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program ZURICH, Switzerland, April 01, 2026 (GLOBE...
Clinical Trial
A Kaleidoscope Inspires the Foundation for Sarcoidosis “See Sarcoidosis” Global Campaign for Sarcoidosis Awareness Month
CHICAGO, April 01, 2026 (GLOBE NEWSWIRE) -- Often described as a “snowflake disease,” sarcoidosis can affect every patient differently, making...
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow...
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
Fast Track designation is one of the FDA’s expedited programs meant to facilitate development and expedite review of new drugs...
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to...
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated...
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
Axsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor Acquisition further expands Axsome’s industry-leading CNS...
Apollomics Inc. Announces $2.0 Million Bridge Financing
FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that...
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
Engagement will assess KALA’s clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platformTORONTO, April 01, 2026...
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of...
Cardiol Therapeutics Announces Year-End 2025 Update on Operations
Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected...
WEED Inc (OTCQB:BUDZ) Looks to Advance a High-Value AI Data Center Opportunity for The Four Winds of Lake Erie, LLC. On Our Prime Lake Erie Waterfront Property
WEED Inc. ("WEED" or the "Company") is a global cannabis & hemp bioresearch company based in the USA, focused on...
Smart Approach to Marijuana Files Lawsuit to Block Medicare’s CBD “Shortcut” – MMJ Moves Forward With FDA Drug Development
"CMS plays an important role in expanding access to healthcare services, but it does not have the legal authority or...
Mediaspace Health Launches to Deliver Innovative Media Strategies for Agencies, Pharma and Healthcare Brands
Independent Full-Service Company Brings Decades of Specialized Industry Expertise to Healthcare Media PlanningMINNEAPOLIS, March 31, 2026 /PRNewswire/ -- Leading independent...
Mediaspace Health Launches to Deliver Innovative Media Strategies for Agencies, Pharma and Healthcare Brands
Independent Full-Service Company Brings Decades of Specialized Industry Expertise to Healthcare Media PlanningMINNEAPOLIS, March 31, 2026 /PRNewswire/ -- Leading independent...
Clariness Announces Jim Corrigan as CEO to Lead Next Phase of Growth
Company also unveils integrated executive leadership team to drive scalable executionAUSTIN, Texas, March 31, 2026 /PRNewswire/ -- Clariness, backed by...
LabConnect Launches SampleGISTICS® 2.0 to Digitize Clinical Trial Sample Capture
Smartphone-based solution streamlines site workflows and enables real-time visibility at the sample levelRALEIGH, N.C., March 31, 2026 /PRNewswire/ -- LabConnect, a...
60 Degrees Pharmaceuticals Announces 2025 Annual Results
FY 2025 net product revenues increased 65% to $1,005,000Current shelf capacity exhausted after raise of $4 million through an ATM...
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1...
Hemogenyx Pharmaceuticals PLC Announces Tech Transfer Completion and Clinical Trial Update
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS...